Please login to the form below

Not currently logged in
Email:
Password:

Teva/Pfizer settle Neurontin suit

Teva Pharmaceutical has announced it has settled a patent dispute with Pfizer concerning generic versions of Pfizer's Neurontin (gabapentin) – a drug marketed for pain management and the treatment of epilepsy

Teva Pharmaceutical has announced it has settled a patent dispute with Pfizer concerning generic versions of Pfizer's Neurontin (gabapentin) – a drug marketed for pain management and the treatment of epilepsy.

The Israel-based generic manufacturer said litigation related to capsules and tablets sold by the company and its subsidiary Ivax Pharmaceuticals has been 'dismissed' by United States District Court for the District of New Jersey in accordance with a settlement reached between the two parties.

Teva did not reveal financial details of the settlement, but reports have suggested it is less than $100m.

Pfizer had filed litigation claiming that Teva's generic version infringed a patent that expires in 2017, with the US-based drugmaker seeking compensation for profit lost due to competition.

A generic gabapentin was launched by Ivax in 2004. Teva later purchased Ivax in 2006.

1st June 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

segmentation_pie_thumb.jpg
If you’re not thinking segmentation, you’re not thinking
Having a background in market research I’ve been lucky to work on a number of customer segmentations in my time but working in creative communications it is still too rare...
Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
The 16th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD)conference took place at the Hilton Madrid Airport hotel on 15–16 May 2018....
Londonvelophobia (fear of cycling in London) – debunked
...

Infographics